Use of trifunctionel antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy

摘要

The present invention refers to the use of allogenic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties: a) binding to a T cell b) binding to at least one antigen on a tumor cell c) binding via their Fc portion in the case of trifunctional bispecific antibodies or via third specificity in the case of trispecific antibodies to Fc receptor positive cells said antibodies redirecting the allogenic cells away from host tissues in order to substantially reduce or avoid a graft versus host disease for the manufacture of a medicament for treating tumor growth and metastasis in a mammal.